Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

OGX-011 and Docetaxel in Treating Patients With Metastatic or Locally Recurrent Solid Tumors

This study has been completed.
Sponsor:
Information provided by:
NCIC Clinical Trials Group
ClinicalTrials.gov Identifier:
NCT00471432
First received: May 8, 2007
Last updated: November 7, 2010
Last verified: March 2010
  Purpose

RATIONALE: OGX-011 may kill tumor cells by blocking some of the proteins that may cause tumor cells to grow. Drugs used in chemotherapy, such as docetaxel, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving OGX-011 together with docetaxel may kill more tumor cells.

PURPOSE: This phase I trial is studying the side effects and best dose of OGX-011 when given together with docetaxel in treating patients with metastatic or locally recurrent solid tumors.


Condition Intervention Phase
Bladder Cancer
Breast Cancer
Kidney Cancer
Lung Cancer
Ovarian Cancer
Prostate Cancer
Unspecified Adult Solid Tumor, Protocol Specific
Drug: custirsen sodium
Drug: docetaxel
Other: pharmacological study
Phase 1

Study Type: Interventional
Study Design: Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase I Study of a Second Generation Clusterin Antisense Oligonucleotide (OGX-011) in Combination With Docetaxel

Resource links provided by NLM:


Further study details as provided by NCIC Clinical Trials Group:

Primary Outcome Measures:
  • Dose-limiting toxicity [ Designated as safety issue: Yes ]
  • Recommended phase II dose of OGX-011 [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Pharmacokinetic profile [ Designated as safety issue: No ]
  • Serum clusterin levels and clusterin expression in peripheral blood mononuclear cells and accessible tumors [ Designated as safety issue: No ]
  • Objective response [ Designated as safety issue: No ]

Estimated Enrollment: 30
Study Start Date: March 2003
Study Completion Date: December 2009
Detailed Description:

OBJECTIVES:

Primary

  • Determine the dose-limiting toxicity and recommended phase II dose of OGX-011 when administered with docetaxel in patients with metastatic or locally recurrent solid tumors.

Secondary

  • Determine the pharmacokinetic profile of this regimen in these patients.
  • Assess the effect of OGX-011 on serum clusterin levels and clusterin expression in peripheral blood mononuclear cells and accessible tumors.
  • Assess objective response in patients treated with this regimen.

OUTLINE: This is an open-label, multicenter, dose-escalation study of OGX-011. Patients are sequentially assigned to 1 of 2 treatment schedules.

  • Schedule A: Patients receive OGX-011 IV over 2 hours on days 1, 3, 5, 8, 15, 22, 29, and 36 of course 1 and once weekly in weeks 1-6 of all subsequent courses. Patients also receive docetaxel IV over 1 hour once weekly in weeks 1-5. Treatment repeats every 6 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity.
  • Schedule B: Patients receive OGX-011 IV over 2 hours on days -7, -5, -3, 1, 8, and 15 of course 1 and days 1, 8, and 15 of all subsequent courses. Patients also receive docetaxel IV over 1 hour on day 1. Treatment repeats every 3 weeks (course 1 is 4 weeks in duration) for up to 4 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of OGX-011 (in each schedule) until the recommended phase II dose (RPTD) is determined. The RPTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.

Patients undergo serum collection periodically for pharmacokinetic and pharmacodynamic analysis.

After completion of study treatment, patients are followed at 4 weeks and then every 3 months thereafter.

PROJECTED ACCRUAL: A total of 30 patients will be accrued for this study.

  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

DISEASE CHARACTERISTICS:

  • Histologically or cytologically confirmed solid tumors that have been shown to overexpress clusterin, including but not limited to, any of the following:

    • Prostate cancer
    • Renal cell carcinoma
    • Non-small cell lung cancer
    • Bladder cancer
    • Breast cancer
    • Ovarian cancer
  • Metastatic or locally recurrent disease
  • Refractory to standard curative therapy or no standard curative therapy exists

    • Patients with prostate cancer must be hormone refractory (i.e., have documented evidence of progression while receiving androgen ablative therapy)
  • Measurable or nonmeasurable disease

    • Measurable disease defined as measurable lesion ≥ 20 mm by x-ray, physical exam, or nonspiral CT scan or ≥ 10 mm by spiral CT scan
  • No documented CNS metastases
  • Hormone receptor status not specified

PATIENT CHARACTERISTICS:

  • Menopausal status not specified
  • ECOG performance status 0-2
  • Life expectancy ≥ 12 weeks
  • Absolute granulocyte count ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Bilirubin normal
  • Creatinine ≤ 2 times upper limit of normal (ULN)
  • AST and ALT ≤ 1.5 times ULN
  • PT/INR and PTT normal
  • No uncontrolled pain
  • No known bleeding disorder
  • No history of serious allergic reaction to taxane (paclitaxel or docetaxel)
  • No preexisting peripheral neuropathy ≥ grade 2
  • Not pregnant or nursing
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • No other serious illness or medical conditions that would preclude study compliance, including any of the following:

    • Active uncontrolled infection
    • Significant cardiac dysfunction
  • No significant neurological disorder that would preclude giving informed consent

PRIOR CONCURRENT THERAPY:

  • No prior strontium chloride Sr 89
  • No more than 2 prior chemotherapy regimens, including adjuvant or neoadjuvant chemotherapy (for patients assigned to schedule B [docetaxel once every 3 weeks])
  • More than 4 weeks since prior chemotherapy and recovered
  • At least 4 weeks since prior antiandrogens
  • More than 4 weeks since prior external-beam radiotherapy, except low-dose nonmyelosuppressive radiotherapy
  • No prior radiotherapy to ≥ 30% of marrow-bearing areas (for patients assigned to schedule B [docetaxel once every 3 weeks])
  • At least 28 days since prior new anticancer therapy
  • At least 28 days since prior and no other concurrent investigational agents
  • No concurrent radiotherapy, except low-dose nonmyelosuppressive radiotherapy
  • No other concurrent cytotoxic therapy
  • Concurrent luteinizing hormone-releasing hormone agonist allowed (if already initiated in patients with prostate cancer)
  • No concurrent anticoagulant therapy (i.e., heparin, warfarin)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00471432

Sponsors and Collaborators
NCIC Clinical Trials Group
Investigators
Study Chair: Kim N. Chi, MD British Columbia Cancer Agency
  More Information

Additional Information:
Publications:
ClinicalTrials.gov Identifier: NCT00471432     History of Changes
Other Study ID Numbers: I154, CAN-NCIC-IND154, ONCOGENEX-OGX-01-02, CDR0000547039
Study First Received: May 8, 2007
Last Updated: November 7, 2010
Health Authority: United States: Federal Government

Keywords provided by NCIC Clinical Trials Group:
recurrent prostate cancer
stage IV prostate cancer
recurrent renal cell cancer
stage IV renal cell cancer
recurrent non-small cell lung cancer
stage IV non-small cell lung cancer
recurrent bladder cancer
stage IV bladder cancer
recurrent breast cancer
stage IV breast cancer
recurrent ovarian epithelial cancer
stage IV ovarian epithelial cancer
unspecified adult solid tumor, protocol specific
male breast cancer

Additional relevant MeSH terms:
Breast Neoplasms
Carcinoma, Renal Cell
Kidney Neoplasms
Lung Neoplasms
Ovarian Neoplasms
Prostatic Neoplasms
Urinary Bladder Neoplasms
Adenocarcinoma
Adnexal Diseases
Breast Diseases
Carcinoma
Endocrine Gland Neoplasms
Endocrine System Diseases
Genital Diseases, Female
Genital Diseases, Male
Genital Neoplasms, Female
Genital Neoplasms, Male
Gonadal Disorders
Kidney Diseases
Lung Diseases
Neoplasms
Neoplasms by Histologic Type
Neoplasms by Site
Neoplasms, Glandular and Epithelial
Ovarian Diseases
Prostatic Diseases
Respiratory Tract Diseases
Respiratory Tract Neoplasms
Skin Diseases
Thoracic Neoplasms

ClinicalTrials.gov processed this record on November 20, 2014